Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03457935 · ClinicalTrials.gov registry record
Detection of Early Idiopathic Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by Temple University.
- Active
- Registry status
- 450
- Enrollment target
- 1
- Study location
NCT03457935: Active study of Idiopathic Pulmonary Fibrosis, sponsored by Temple University.
NCT03457935 is a study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Temple University. The registered enrollment target is 450 participants, below the 743-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03457935, a study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Temple University.
- ACTIVE NOT RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
Primary Outcome
MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF.
Conditions Studied
Interventions
- OTHER blood samples
Study Locations (1)
Pennsylvania
- Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2026-08-30 |
What the registry record for NCT03457935 still lists
NCT03457935 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 743-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which blood samples is the first listed.
NCT03457935 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03457935 about?
NCT03457935 is a clinical study titled "Detection of Early Idiopathic Pulmonary Fibrosis". The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
What is the current status of trial NCT03457935?
This trial is currently active not recruiting. The enrollment target is 450 participants. The study started on 2018-04-10. Estimated completion is 2026-08-30.
What conditions does trial NCT03457935 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT03457935?
The interventions under investigation include: blood samples (OTHER).
Who is sponsoring clinical trial NCT03457935?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03457935 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03457935's enrollment target sits among peer trials
450 11th of 51 higher than 41 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI